The Effects of Testicular Cancer Treatment on Health-related Quality of Life

Vidrine, Damon J.; Hoekstra-Weebers, Josette E. H. M.; Hoekstra, Harald J.; Tuinman, Marrit A.; Marani, Salma K.; Gritz, Ellen R.

doi:10.1016/j.urology.2009.09.053

Cited by 28 publications

(19 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Aberger et al (2014) suggests there is an average of 2.4:1 cost-benefit ratio between cases of TCa detected early versus more advanced-stage cases. In terms of quality of life, Vidrine et al (2010) and Haugnes et al (2012) discuss TCa treatment and resultant quality of life among patients. These pieces allow the reader to understand the positive impact TCa management has on survivorship as well as the negative impact it has on quality of life, particularly if management involves chemotherapy.…”

Section: Our Responsementioning

confidence: 99%

“Off-Label” Usage of Testicular Self-Examination (TSE): Benefits Beyond Cancer Detection

2015

View full text Add to dashboard Cite

Testicular cancer (TCa) is the most common cancer among 15- to 34-year-old males. Treatments are highly effective, which help foster approximately 98% 5-year survival rate. There are very few known causal factors of the disease (e.g., cryptorchidism and family history), thus possibly limiting primary prevention methods. Secondary preventative measures, on the other hand, most notably testicular self-examination (TSE), are well-known and are promoted to help prevent late-stage diagnosis of TCa. However, debate ensues as to whether or not TSE provides any benefit. In light of a recent systematic review conducted by these authors assessing the effectiveness of TSE promotion interventions, we propose that the behavior can serve as a tool not just for detection of TCa, but other male-specific urogenital health concerns, including varicoceles, hydroceles, among others. Furthermore, we suggest that TSE can also help foster informed decision-making skills among males with regard to health concerns and treatment options. However, our advocacy is in direct conflict with U.S. Preventive Services Task Force's influential "D" rating of TSE and others who recommend against performing TSE. This article offers an overview of the dispute over TSE's purpose and net benefit. We conclude that TSE is a behavior that is beneficial beyond detecting cancer. These proposed "off-label" uses of the procedure make for an effectual means to promote testicular health, self-awareness, and wellness among males. Recommendations for future research and advocacy are presented to the academy.

show abstract

Section: Our Responsementioning

confidence: 99%

“Off-Label” Usage of Testicular Self-Examination (TSE): Benefits Beyond Cancer Detection

2015

View full text Add to dashboard Cite

show abstract

“…Testicular germ cell tumour (TGCT), although relatively rare, is the most common malignancy in men between 15 and 35 years old age group with increasing incidence in the past decades [1, 2]. TGCTs have become one of the most curable solid neoplasms, due to the advantage of diagnostic and therapeutic methods, but still the prognosis of highly advanced cases with bulky metastatic lesions is generally poor.…”

Section: Introductionmentioning

confidence: 99%

Expression of Syndecan-4 and Correlation with Metastatic Potential in Testicular Germ Cell Tumours

Labropoulou

Skandalis

Ravazoula

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

Although syndecan-4 is implicated in cancer progression, there is no information for its role in testicular germ cell tumours (TGCTs). Thus, we examined the expression of syndecan-4 in patients with TGCTs and its correlation with the clinicopathological findings. Immunohistochemical staining in 71 tissue specimens and mRNA analysis revealed significant overexpression of syndecan-4 in TGCTs. In seminomas, high percentage of tumour cells exhibited membranous and/or cytoplasmic staining for syndecan-4 in all cases. Stromal staining for syndecan-4 was found in seminomas and it was associated with nodal metastasis (P = 0.04), vascular/lymphatic invasion (P = 0.01), and disease stage (P = 0.04). Reduced tumour cell associated staining for syndecan-4 was observed in nonseminomatous germ cell tumours (NSGCTs) compared to seminomas. This loss of syndecan-4 was associated with nodal metastasis (P = 0.01), vascular/lymphatic invasion (P = 0.01), and disease stage (P = 0.01). Stromal staining for syndecan-4 in NSGCTs did not correlate with any of the clinicopathological variables. The stromal expression of syndecan-4 in TGCTs was correlated with microvessel density (P = 0.03). Our results indicate that syndecan-4 is differentially expressed in seminomas and NSGCTs and might be a useful marker. Stromal staining in seminomas and reduced levels of syndecan-4 in tumour cells in NSGCTs are related to metastatic potential, whereas stromal staining in TGCTs is associated with neovascularization.

show abstract

“…Most studies indicate that overall health-related quality of life (QOL) is similar among testis cancer survivors and the general population [1][2][3][4][5][6][7][8][9]. Although QOL clearly deteriorates at the time of diagnosis and during treatment, it subsequently returns to normal levels, as defined by matched controls or the general age-matched population.…”

mentioning

confidence: 99%